Author, country [Ref.] | Study design | Study setting | Marker (assay) | Patient population | Control population | Age and sex | |
---|---|---|---|---|---|---|---|
Patient | Control | ||||||
Diastolic dysfunction | |||||||
Bakowski, EU [20] | Cross-sectional | Secondary | ANP and BNP (RIA) | AMB patients with AF (N = 27) | AMB patients with AF (N = 15) | 58.6 ± 8.2 y; 45.2% F* | |
Bettencourt, EU [76] | Case-control | Tertiary | BNP (RIA) | AMB referrals (N = 17) | Healthy controls (N = 9) | 71 (11) y; 52.9% F | 65 (7) y; 44.4% F |
Crowson, USA [74] | Case-control | Primary | BNP (FEIA) | Non-RA participants (N = 82) | Non-RA participants (N = 1455) | Non-RA: 61.3 ± 10.1 y; 55%F* | |
Goto, AS [47] | Cross-sectional | Secondary | BNP (RIA) | AMB CAD patients with AP (N = 91) | AMB CAD patients with AP (N = 189) | 67.4 ± 8.2 y; 18.7% F | 66.3 ± 8.5 y; 30.7% F |
Grewal, CA + EU [48] | Cross-sectional | Primary | BNP (RIA) and NT-proBNP | AMB HFpEF patients (N = 72) | AMB HFpEF patients (N = 109) | 70 ± 10 y; 35% F | 65 ± 12 y; 35% F |
Karaca, EU [77] | Case-control | Tertiary | BNP (FEIA) | AMB HTN patients (N = 30) | Healthy controls (N = 20) | 53 ± 9.2 y; 40% F | 44 ± 4.8 y; 45% F |
Lukowicz, EU [78] | Case-control | Primary | BNP (RIA) | General population (N = 38) | General population with SD (N = 16) | 57 ± 10 y; 42% F | 57 ± 4 y; 38% F |
Mak, NA [49] | Cross-sectional | Tertiary | BNP (FEIA) | Echo referrals (N = 16) | Echo referrals (N = 84) | 64 ± 13 y; 3% F* | |
Mannacio, EU [50] | Cross-sectional | Tertiary | BNP (FEIA) | Hospitalised patients (N = 25) | Hospitalised patients (N = 14) | 67 ± 8.6 y; 31.9% F* | |
Martos, EU [38] | Cross-sectional | Tertiary | BNP (FEIA) | AMB HTN patients (N = 33) | AMB HTN patients (N = 20) | 68 ± 9 y; 24% F | 64 ± 10 y; 25% F |
Redfield, USA [22] | Cross-sectional | Primary | BNP (FEIA) | Random residents (N = 137) | Random residents (N = 1817) | Random: 62 ± 11 y; 52% F* | |
Wei, AS [51] | Cross-sectional | Secondary | BNP (FEIA) | AMB HTN patients (N = 61) | AMB HTN patients (N = 74) | 70 ± 10 y; 32% F | 66 ± 13 y; 35% F |
Zapata, EU [52] | Cross-sectional | Secondary | BNP (FEIA) and NT-proBNP | ICU patients (N = 50) | ICU patients (N = 36) | Mild DD: 68 ± 11 y; 51% F | 57 ± 13 y; 19% F |
Moderate DD: 72 ± 5 y, 17% F | |||||||
Severe DD: 69 ± 9 y; 33% F | |||||||
Zuber, EU [53] | Cross-sectional | Tertiary | BNP (FEIA) | AMB patients (N = 7) | AMB patients (N = 129) | 64 (range 19–88) y* | |
Ansari, EU [43] | Cross-sectional | Tertiary | NT-proBNP | AMB HFpEF patients (N = 11) | AMB HFpEF patients (N = 14) | 65 (range:22–97) y; 49% F* | |
Barragan, EU [44] | Cross-sectional | Tertiary | NT-proBNP | AMB DOE patients (N = 45) | AMB DOE patients (N = 37) | 61.4 ± 12.7 y; 87% F | 43.2 ± 13.2 y; 59% F |
Barutçuoğlu, EU [45] | Cross-sectional | Tertiary | NT-proBNP | AMB HTN patients (N = 122) | AMB HTN patients (N = 119) | 55 ± 14 y; 61% F | 53 ± 18 y; 67% F |
Corteville, USA [46] | Cross-sectional | Tertiary | NT-proBNP | AMB CHD patients (N = 78) | AMB CHD patients (N = 652) | < 100 pg/mL NT-proBNP: 62 ± 10 y; 19% F* | |
100–500 pg/mL NT-proBNP: 68 ± 10 y; 21% F* | |||||||
> 500 pg/mL NT-proBNP: 73 ± 10 y; 11% F* | |||||||
Kasner, EU [73] | Case-cohort | Tertiary | NT-proBNP | AMB HFpEF patients (N = 107) | AMB patients with chest discomfort (N = 73) | 53 (17) y; 40% F | 51 (16) y; 43% F |
Mishra, USA [54] | Cross-sectional | Tertiary | NT-proBNP | AMB CKD patients (N = 284) | AMB CKD patients (N = 2384) | Quartiles of NT-proBNP | |
Q1: 54 (12) y; 35% F* | |||||||
Q4: 62 (10) y; 47% F* | |||||||
Mocan, EU [55] | Cross-sectional | Secondary | NT-proBNP (ELISA) | Hospitalised MetS patients (N = 47) | Hospitalised MetS patients (N = 25) | 59.2 ± 5.3 y; 64% F* | |
Ravassa, EU [56] | Cross-sectional | Primary | NT-proBNP (EIA) | General population (N = 186) | General population (N = 541) | 51.3 ± 15.4 y; 51.2% F* | |
Tekten, EU [57] | Cross-sectional | Tertiary | NT-proBNP | AMB HTN patients with DD grade 1 (N = 18) or grade 2 (N = 10) | AMB HTN patients (N = 12) | Grade 1/2: 52 ± 5 y; 67% F 54 ± 8 y; 60% F | 51 ± 5 y; 67% F |
Tschöpe, EU [18] | Cross-sectional | Tertiary | NT-proBNP | AMB DOE patients (N = 68) | AMB patients (N = 50) | 51 ± 9 y; 46% F | 49 ± 10 y; 44% F |